A Phase 2 interventional study of Efgartigimod in Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome, sponsored by argenx. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-23.
Sponsored by argenx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States — 19 open to participants now, 42 under way, none of them phase 3. Postural Orthostatic Tachycardia Syndrome · United States.
Among the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States, this one is the 35th largest by enrollment of the 67 interventional ones that give a count, is one of 9 that started in 2023, is one of 10 in phase 2, and was the 73rd registered.
136 studies on the registry are indexed under Postural Orthostatic Tachycardia Syndrome; 42 are open to participants now.
Browse Postural Orthostatic Tachycardia Syndrome studies →19 of the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Blueprint Medicines Corporation · Sites in United States, Belgium
Ages 18+
Stanford University · Sites in United States
Ages 18+
Virginia Commonwealth University · Sites in United States
Ages 12–21 · Women only · Healthy volunteers
University of Texas Southwestern Medical Center · Sites in United States
Ages 14+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 29 Postural Orthostatic Tachycardia Syndrome studies recruiting now, 9 (31%) set no upper age limit and 16 (55%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 15 · Phase 3 3 · Phase 4 1
First in 1994; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is close to the median of 36 across 102 interventional studies indexed under Postural Orthostatic Tachycardia Syndrome.
Median enrollment 36 across the 67 interventional studies, 100 across the 25 observational. Of the 49 that completed or were terminated, 19 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 92 have an industry lead sponsor. The 10 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
argenx has 2 studies filed under Postural Orthostatic Tachycardia Syndrome — fewer than ten, so there is no comparison to draw.
11 of the studies in Postural Orthostatic Tachycardia Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00962728Alfredo GamboaBreathing Device in Postural Orthostatic Tachycardia Syndrome (POTS) | 2026-11 |
| NCT07197905Vanderbilt University Medical CenterRestoring Iron Deficiency in POTS | 2026-12 |
| NCT01988883Vanderbilt University Medical CenterModafinil and Cognitive Function in POTS | 2026-12 |
| NCT01783288Vanderbilt UniversityAldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening | 2026-12 |
| NCT05618054Virginia Commonwealth UniversityPeriaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities? | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.
Study ARGX-113-2105 is a long-term, single-arm, open-label, multicenter extension of the ARGX-113-2104 study, designed to evaluate the long-term safety of efgartigimod IV in adult patients with PC-POTS. Participants will be enrolled from both active and placebo arms of the ARGX-113-2104 study and will receive efgartigimod IV 10 mg/kg in the extension study without knowledge of their prior treatment arm. To be eligible to enroll in this study, participants must have completed the 24-week treatment period of the ARGX-113-2104 study and must not have permanently discontinued the IMP in that study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receive efgartigimod IV 10mg/kg infusions during a treatment period of 48 weeks
Drug: Efgartigimod
Participants will receive efgartigimod IV 10 mg/kg open label, respectively.
Number of Participants With TEAEs, TESAEs and TEAESIs
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. An adverse event of special interest (AESI) was an AE of scientific and medical concern specific to the sponsor's product or program. Treatment-emergent adverse events (TEAEs) were defined as AEs with onset on or after the first administration of study drug up to and including 60 days after the last study drug administration.
Time frame: From the first dose of study drug (Day 1) up to 60 days post last dose of study drug, up to 383 days
Change From Baseline to Weeks 24 and 48 in the COMPASS 31 (2-week Recall Version)
Composite Autonomic Symptom Score (COMPASS) 31 modified version (2-week recall) is a self-rated questionnaire to evaluate the severity and distribution of autonomic symptoms in various autonomic nerve disorders. It consists of 31 questions in 6 weighted domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal {GI}-mixed upper and diarrhea, bladder, and pupillomotor). A weighted total score of 0 (mild) to 100 (severe) was determined by adding a maximum raw score for each domain. Higher scores indicated a more severe degree of autonomic symptoms.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Change From Baseline to Weeks 24 and 48 in the MaPS
The Malmö POTS Symptom Score (MaPS) score is a dedicated POTS symptom scoring questionnaire. The score consists of 12 questions that assess symptom burden related (tachycardia, palpitations, dizziness, presyncope) and unrelated to orthostatic intolerance (GI symptoms, insomnia, concentration difficulties). Participants graded their symptoms for the past 7 days using a numerical rating scale ranging from 0 (no symptoms) to 10 (very pronounced symptoms). The total score was calculated by summing up the items/individual items and range was 0 to 120 points, with higher scores indicating more severe symptoms.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Percentage of Participants With Improved PGI-S at Weeks 24 and 48
The Patient Global Impression-Severity (PGI-S) is a participant-rated, single-item scale to assess the severity of a health condition. The scale was used to assess the severity of symptoms over the past week (1-week recall) and overall experience of symptoms over the past 2 weeks (2-week recall). Both were rated on a 4-point type Likert scale, with scores ranging from 1 (none), 2 (mild), 3 (moderate), and 4 (severe). Higher scores indicate greater symptom severity. An "improved PGI-S" was defined by a change from baseline of -3, -2 and -1.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Percentage of Participants With Improved PGI-C at Weeks 24 and 48
The Patient Global Impression-Change (PGIC) is a single-item scale to capture the participant's perception of an overall change in their symptoms from start of study drug. It was rated on a 7-point Likert scale, with scores ranging from 1 (much better), 2 (somewhat better), 3 (a little better), 4 (no change), 5 (a little worse), 6 (somewhat worse), and 7 (much worse). Higher PGI-C scores signify worse outcome. An "improved PGI-C" was defined by a change from baseline of 1, 2 and 3.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Change From Baseline to Weeks 24 and 48 in the PROMIS Fatigue Short Form 8a
The Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8a assesses the impact and perceived fatigue during the last 7 days. This validated 8-question scale has 5 response options, with scores ranging from 1 (not at all) to 5 (very much). Total scores ranged from 8 to 40; higher scores indicated higher fatigue levels and were converted to a T-score with a mean of 50 and standard deviation of 10. A decrease in T-score (negative change from baseline) indicated improvement in fatigue.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Change From Baseline to Weeks 24 and 48 in the PROMIS Cognitive Function Short Form 6a
PROMIS Cognitive Function Short Form 6a assesses the frequency of cognitive difficulties experienced in the past 7 days. The questionnaire comprises 6 questions on subjective cognitive difficulties regarding a participant's concentration, memory, language, mental acuity, and perceived changes in cognitive functioning. The participant marks their response on a 5-point Likert scale (1: never and 5: very often). Scores ranged from 6 to 30; higher scores indicated worse perceived cognitive functioning and were converted to a T-score with a mean of 50 and standard deviation of 10. An increase in T-score (positive change from baseline) indicated better cognitive function.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Percent Change From Baseline in Total IgG Levels at Weeks 24 and 48
Blood samples for immunoglobulin G (IgG) analysis were collected at specified time points. Total IgG concentrations were quantified using validated methods at a central laboratory.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Serum Concentration of Efgartigimod
Serum samples were collected at specified timepoints to determine the concentration of efgartigimod.
Time frame: Pre-dose at Baseline (Day 1) and Weeks 1, 4, 12 and 24
Number of Participants With ADAs Against Efgartigimod
Blood samples were collected at specified timepoints to assess anti-drug antibodies (ADAs) against efgartigimod. ADA incidence reported here was defined as total number of participants with treatment-induced and treatment-boosted ADA. Treatment-induced ADA was defined as a baseline negative sample and at least 1 positive post-baseline sample. Treatment-boosted ADA was defined as a baseline positive sample and the titer value increased 4-fold or more compared to baseline.
Time frame: From the first dose of study drug (Day 1) up to Week 48
This open-label study was an extension of ARGX-113-2104 study (NCT05633407) and was conducted at 9 sites in the United States from 26-Jun-23 to 15-Aug-24 in participants with post-coronavirus disease 2019 (COVID-19) postural orthostatic tachycardia syndrome (PC-POTS).
| Milestone | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Started | 20 | 13 |
| Completed | 1 | 0 |
| Not completed | 19 | 13 |
| Withdrew: Study terminated by sponsor | 17 | 11 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Other | 0 | 1 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. An adverse event of special interest (AESI) was an AE of scientific and medical concern specific to the sponsor's product or program. Treatment-emergent adverse events (TEAEs) were defined as AEs with onset on or after the first administration of study drug up to and including 60 days after the last study drug administration.
| Participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| TEAEs | 13 | 12 |
| TESAEs | 0 | 0 |
| TEAESIs | 7 | 5 |
Composite Autonomic Symptom Score (COMPASS) 31 modified version (2-week recall) is a self-rated questionnaire to evaluate the severity and distribution of autonomic symptoms in various autonomic nerve disorders. It consists of 31 questions in 6 weighted domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal {GI}-mixed upper and diarrhea, bladder, and pupillomotor). A weighted total score of 0 (mild) to 100 (severe) was determined by adding a maximum raw score for each domain. Higher scores indicated a more severe degree of autonomic symptoms.
| score on a scale | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 13.608 ± 29.7026 | 8.447 ± 18.1170 |
| Week 48 | 1.780 | — |
The Malmö POTS Symptom Score (MaPS) score is a dedicated POTS symptom scoring questionnaire. The score consists of 12 questions that assess symptom burden related (tachycardia, palpitations, dizziness, presyncope) and unrelated to orthostatic intolerance (GI symptoms, insomnia, concentration difficulties). Participants graded their symptoms for the past 7 days using a numerical rating scale ranging from 0 (no symptoms) to 10 (very pronounced symptoms). The total score was calculated by summing up the items/individual items and range was 0 to 120 points, with higher scores indicating more severe symptoms.
| score on a scale | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | -0.8 ± 22.02 | 10.3 ± 24.95 |
| Week 48 | -17.0 | — |
The Patient Global Impression-Severity (PGI-S) is a participant-rated, single-item scale to assess the severity of a health condition. The scale was used to assess the severity of symptoms over the past week (1-week recall) and overall experience of symptoms over the past 2 weeks (2-week recall). Both were rated on a 4-point type Likert scale, with scores ranging from 1 (none), 2 (mild), 3 (moderate), and 4 (severe). Higher scores indicate greater symptom severity. An "improved PGI-S" was defined by a change from baseline of -3, -2 and -1.
| percentage of participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24, 1-week recall | 12.5 | 0 |
| Week 24, 2-week recall | 12.5 | 0 |
| Week 48, 1-week recall | 25.0 | 0 |
| Week 48, 2-week recall | 25.0 | 0 |
The Patient Global Impression-Change (PGIC) is a single-item scale to capture the participant's perception of an overall change in their symptoms from start of study drug. It was rated on a 7-point Likert scale, with scores ranging from 1 (much better), 2 (somewhat better), 3 (a little better), 4 (no change), 5 (a little worse), 6 (somewhat worse), and 7 (much worse). Higher PGI-C scores signify worse outcome. An "improved PGI-C" was defined by a change from baseline of 1, 2 and 3.
| percentage of participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 100.0 | 100.0 |
| Week 48 | 100.0 | 75.0 |
The Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8a assesses the impact and perceived fatigue during the last 7 days. This validated 8-question scale has 5 response options, with scores ranging from 1 (not at all) to 5 (very much). Total scores ranged from 8 to 40; higher scores indicated higher fatigue levels and were converted to a T-score with a mean of 50 and standard deviation of 10. A decrease in T-score (negative change from baseline) indicated improvement in fatigue.
| T-score | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 3.0 ± 4.93 | 2.6 ± 9.74 |
| Week 48 | -3.5 ± 3.42 | 1.0 ± 5.94 |
PROMIS Cognitive Function Short Form 6a assesses the frequency of cognitive difficulties experienced in the past 7 days. The questionnaire comprises 6 questions on subjective cognitive difficulties regarding a participant's concentration, memory, language, mental acuity, and perceived changes in cognitive functioning. The participant marks their response on a 5-point Likert scale (1: never and 5: very often). Scores ranged from 6 to 30; higher scores indicated worse perceived cognitive functioning and were converted to a T-score with a mean of 50 and standard deviation of 10. An increase in T-score (positive change from baseline) indicated better cognitive function.
| T-score | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | -2.2 ± 7.36 | -4.0 ± 5.97 |
| Week 48 | -8.0 | — |
Blood samples for immunoglobulin G (IgG) analysis were collected at specified time points. Total IgG concentrations were quantified using validated methods at a central laboratory.
| percent change | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Week 24 | 32.684 ± 28.6347 | -59.636 ± 6.2440 |
| Week 48 | -10.360 | — |
Serum samples were collected at specified timepoints to determine the concentration of efgartigimod.
| microgram/milliliter (mcg/mL) | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Day 1 | 9 ± 4 | — |
| Week 1 | 10 ± 4 | 11 ± 4 |
| Week 4 | 11 ± 4 | 12 ± 4 |
| Week 12 | 3 ± 3 | 7 ± 6 |
| Week 24 | 5 ± 5 | 2 ± 2 |
Blood samples were collected at specified timepoints to assess anti-drug antibodies (ADAs) against efgartigimod. ADA incidence reported here was defined as total number of participants with treatment-induced and treatment-boosted ADA. Treatment-induced ADA was defined as a baseline negative sample and at least 1 positive post-baseline sample. Treatment-boosted ADA was defined as a baseline positive sample and the titer value increased 4-fold or more compared to baseline.
| Participants | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| Number of Participants With ADAs Against Efgartigimod | 1 | 1 |
Collected over From the first dose of study drug (Day 1) up to 60 days post last dose of study drug, up to 383 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efgartigimod-Efgartigimod | 0/20 (0%) | 0/20 (0%) | 13/20 (65%) |
| Placebo-Efgartigimod | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| Event | Efgartigimod-Efgartigimod | Placebo-Efgartigimod |
|---|---|---|
| COVID-19Infections and infestations | 5/20 | 1/13 |
| FatigueGeneral disorders | 2/20 | 3/13 |
| NauseaGastrointestinal disorders | 3/20 | 2/13 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/20 | 2/13 |
| Back painMusculoskeletal and connective tissue disorders | 2/20 | 0/13 |
| HeadacheNervous system disorders | 2/20 | 1/13 |
| SyncopeNervous system disorders | 2/20 | 1/13 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/20 | 0/13 |
| Ear discomfortEar and labyrinth disorders | 0/20 | 1/13 |
| TinnitusEar and labyrinth disorders | 0/20 | 1/13 |
Analysis was performed on full analysis set (FAS) which included all enrolled participants.
| Age, Continuous(years) | Efgartigimod-Efgartigimod | Placebo-Efgartigimod | Total |
|---|---|---|---|
| Mean | 33.2 ± 11.38 | 38.0 ± 11.40 | 35.1 ± 11.46 |
| Sex: Female, Male(Participants) | Efgartigimod-Efgartigimod | Placebo-Efgartigimod | Total |
|---|---|---|---|
| Female | 15 | 11 | 26 |
| Male | 5 | 2 | 7 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod-Efgartigimod | Placebo-Efgartigimod | Total |
|---|---|---|---|
| Asian | 1 | 0 | 1 |
| Black or African American | 1 | 0 | 1 |
| White | 16 | 13 | 29 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod-Efgartigimod | Placebo-Efgartigimod | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 5 |
| Not Hispanic or Latino | 18 | 10 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2023 to primary completion in Aug 2024, 13 months.
Results were first posted in Oct 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efgartigimod alfa
Postural Orthostatic Tachycardia Syndrome →